Southampton looking at GA-101

[Guest guest]

Dr. Hamblin's old lab is looking into GA-101 and how it works.

Mark Cragg and Tim Illidge et al have found that certain type II anti-CD20 mAbs,

like GA-101, efficiently induce programmed cell death, whereas rituximab-like

type I anti-CD20 mAbs do not.

Further, they demonstrated that GA101-induced cell death is dependent on actin

reorganization, can be abrogated by inhibitors of actin polymerization and is

independent of BCL-2 over-expression and caspase activation.

GA101-induced programmed cell death is executed by lysosomes which disperse

their contents into the cytoplasm and surrounding environment.

In conclusion it is felt that GA101 is able to potently elicit actin-dependent,

lysosomal cell death, which may potentially lead to improved clearance of B-cell

malignancies in vivo.

Abstract:

http://bloodjournal.hematologylibrary.org/cgi/content/abstract/blood-2010-07-296\

913v1

~chris